Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Agilent Announces Enhanced Mass Spectrometry and Automation Software Solutions to Support Regulatory Compliance Guidelines


Agilent Technologies Inc. (NYSE: A) today announced the release of MassHunter Workstation Plus 11.0, MassHunter Networked Workstation 11.0, and MassHunter BioConfirm. The latest revision of these software enables data integrity consistent with the regulatory requirements from the US FDA and EU EMEA guidance, providing user management, checksums, tamper detection, and audit trails for MassHunter Acquisition, Quantitative Analysis, and MassHunter BioConfirm. First shipments are expected in June, with quotes available in May.

Support for regulatory requirements as defined in 21 CFR Part 11 and Annex 11 is a key requirement for pharmaceutical and biopharmaceutical manufacturing customers. The need for data integrity solutions is also becoming increasingly crucial for other industries, such as food safety and environmental testing.

In conjunction, Agilent has released VWorks 14.0 Plus, which introduces compliance-enabling features built for the Agilent Bravo Automated Liquid Handling Platform. VWorks Plus extends enabling compliance to automated sample prep on the Bravo and will begin shipping to customers in mid-February 2021.

“The introduction of compliance features in MassHunter and BioConfirm for LC/TOF and LC/Q-TOF ensures that all Agilent’s LCMS platforms meet the regulatory needs of our customers,” said Sudharshana Seshadri, vice president and general manager of Agilent's Mass Spectrometry Division. “This further reinforces Agilent as a leading solutions provider to the pharma/biopharmaceutical industry.”

Agilent has been ranked first in the industry in compliance in numerous consecutive LCGC customer surveys and is committed to providing the most powerful analytical tools for the development of drugs and therapeutics to improve the human condition.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005183/en/

Agilent Technologies Inc. Aktie

116,64 €
0,07 %
Geringfügige Kursveränderung bei Agilent Technologies Inc. um 0,07 % seit dem Vortag.
Die Community sieht Agilent Technologies Inc. leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 129 € für Agilent Technologies Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 116.64 €.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare